CompletedPhase 2NCT05495269
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Studying Sturge-Weber syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Qlaris Bio, Inc.
- Principal Investigator
- Sharon Freedman, M.D.Duke Eye Center
- Intervention
- QLS-101 ophthalmic solution, 2.0 %(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 12-19 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- Duke Eye Center, Durham, North Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05495269 on ClinicalTrials.govOther trials for Sturge-Weber syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04717427Longitudinal Studies to Identify Biomarkers for Sturge-Weber SyndromeUniversity of Illinois at Chicago
- ACTIVE NOT RECRUITINGNANCT04517565Longitudinal Neuroimaging in Sturge-Weber SyndromeWayne State University
- ACTIVE NOT RECRUITINGNCT01425944Innovative Approaches to Gauge Progression of Sturge-Weber SyndromeHugo W. Moser Research Institute at Kennedy Krieger, Inc.